• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

For Some ALS Patients, A New Drug Shows Potential To Slow And Even Reverse Disease Progression

September 22, 2022 by Deborah Bloomfield

A landmark new study has shown once and for all that patience really is a virtue – at least if you’re hoping to change the world. After a slow start, tofersen – an experimental drug being investigated as a treatment for motor neurone disease (MND) aka amyotrophic lateral sclerosis (ALS) – has turned out to be a potentially pretty remarkable therapy for this devastating neurodegenerative disease.

“I have conducted more than 25 MND clinical trials,” said Pamela Shaw, Professor of Neurology at the University of Sheffield, “and the tofersen trial is the first trial in which patients have reported an improvement in their motor function.”

Advertisement

Motor neurone disease is a group of rare and relatively mysterious conditions, characterized by the progressive loss of communication from the brain and spinal cord to the muscles. What may start with a slightly weaker grip or leg cramps slowly but surely becomes an inability to move, swallow, and even breathe: it’s irreversible, progressive, and fatal, and although incredible advances in treatment have been made in recent years, there is still no cure, no “standard” progression, and until now, no definitive known cause.

Except, that is, in around two percent of cases. For those one in fifty ALS patients – and up to one in five of those with a family history of the disease – the cause is a faulty SOD1 gene. 

While it’s not yet known exactly what links one to the other, some of the latest and most promising new therapies for ALS have been based on this relationship. Back in 2020, for example, researchers from the University of Illinois at Urbana-Champaign found success using CRISPR gene-editing technology to “deactivate” SOD1 in mice with the disease, resulting in improved muscle function, slower disease progression, and extended lifespans.

Advertisement

Researchers at the Sheffield Institute for Translational Neuroscience, or SITraN, of which Shaw is Director, took a slightly different approach – though the general idea is the same. T

Tofersen works through a technique called “antisense,” directly interfering with the body’s faulty instructions for making the SOD1 gene. Evidently, though, it takes a little longer to work than originally anticipated – after six months, at the phase 3 trial’s primary endpoint, patients were not showing physical improvements from their tofersen regimen, even while the levels of certain ALS biomarkers their cerebrospinal fluid had dropped significantly.

However, the picture is very different another six months on. “What we have found is that we can reduce or slow damage from happening biologically, but it takes more time for the motor neurones to heal and regenerate their connections with the muscles,” Shaw said in a statement on the result. “So, the motor system needs time to heal before we see a physical and clinical change.”

Advertisement

Not only is this incredible news for the thousands of people worldwide with SOD1 ALS, but the project’s success may potentially translate to treatments for other forms of the disease. Future researchers may be able to extend the approach to counter other harmful proteins – and in doing so, they will be able to exploit the biomarkers found by the team at SITraN to measure the therapies’ success.

“Tofersen is a treatment for only two per cent of those living with MND,” said Chris McDermott, Professor of Translational Neurology at SITraN and a co-author of the study. “We have learned much in doing this clinical trial that will help us do smarter and faster clinical trials in the future.”

With the success of this trial, tofersen has already been accepted for accelerated review by the FDA – and MND groups are already in contact with Biogen, the manufacturer of tofersen, to explore regulatory approval for the drug around the world. If all goes well, patients with SOD1 ALS may soon find themselves with a much better prognosis than they could expect even a few months ago.

Advertisement

“Never before have I heard patients say, ‘I am doing things today that I couldn’t do a few months ago – walking in the house without my sticks, walking up the garden steps, writing Christmas cards’,” said Shaw.

“This trial is going to change the future of MND trials for patients.” 

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Soccer-UEFA chief Ceferin threatens World Cup boycott if new plans go ahead
  2. AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs
  3. Dodging lorries, lava and war, Congo’s skaters feel reborn
  4. Lufthansa gets strong investor backing for 2.1 billion euro cash call

Source Link: For Some ALS Patients, A New Drug Shows Potential To Slow And Even Reverse Disease Progression

Filed Under: News

Primary Sidebar

  • People Are Not Reacting Well After Learning How Cranberries Are Grown
  • The World’s Newest Great Ape Is Also Its Rarest, With Fewer Than 800 Left In The Wild
  • IFLScience We Have Questions: Can Burying Scientists Alive In The Snow Help Us Protect Polar Bears?
  • Scientists Perplexed By 407-Million-Year-Old Fossilized Plant That Doesn’t Follow The Fibonacci Sequence
  • This Giant Goldfish Hybrid Weighs As Much As A 10-Year-Old – A Stark Warning About Dumping Pets
  • Scientists Gave Mice Neanderthal And Denisovan Genes. The Results Were Intriguing
  • 2024 Saw Higher Levels Of Carbon Dioxide In The Atmosphere Than Ever Before
  • Halloween Fireballs Will Grace Our Skies As The Taurid Meteor Showers Arrive
  • Newly Discovered Hunting Megastructures Suggest Pre-Bronze Age Societies More Sophisticated Than Previously Thought
  • What Is Spectroscopy And Why Is It So Important To Science?
  • Parkinson’s “Trigger” Seen For The First Time: Scientists Image The Toxic Molecules Inside The Human Brain
  • What Flying Animals Exist That Are Not Birds?
  • DNA Evidence Uncovers Surprising Origins Of Native Americans
  • Single Gene Swap “Transfers A Behavior” Between Two Species For The First Time
  • Interstellar Object 3I/ATLAS Has A Rare “Anti-Tail”, New Observations Confirm
  • Asteroid Apophis: Animation Shows Asteroid’s Nail-Biting Close Approach To Earth In 2029
  • Titan Breaks A Key Chemistry Rule: What That Means For Alien Life
  • Scientists Studied “Chicago Rat Hole” – They Have Bad News, The South Atlantic’s Magnetic Field Weak Spot Is Growing, And Much More This Week
  • Could This Be The Real Reason Humans Survived And Neanderthals Died Out?
  • Newly Discovered Snail Species Named After Studio Ghibli Co-Founder Is A Hairy Beauty
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version